Clinical Trial

Switching of Sildenafil to Riociguat in CTEPH Patients

Study acronym: S2R
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2025 (before its estimated July 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-03.
Trial Details
NCT Number NCT06715280
Lead Sponsor Chinese University of Hong Kong
Conditions Chronic Thromboembolic Pulmonary Hypertension
Enrollment 30 participants
Start Date 2024-07-25
Primary Completion 2026-07-22 (estimated)
Study Completion 2027-01-22 (estimated)
Updated on ClinicalTrials.gov 2025-05-29